TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07108036: A Study to Assess Anktiva in Patients With Long Covid-19.

Sponsor: ImmunityBio, Inc. · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$352,800

Rescue Site Savings

+$235,200

Unlock Full NCT07108036 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07108036 Rescue Dossier →